

**Montanaro European Smaller Companies Fund****Quarterly Commentary – Q1 2022**

---

**Market review**

**After a difficult start to the year, our Funds stabilised in March, outperforming their respective benchmarks. Clearly, this was not enough to offset the underperformance experienced in January, but it was a sign that investors' enthusiasm for Low-Quality Value stocks may be waning.**

It has been a painful quarter for Quality Growth managers like us. Our Funds recorded one of the worst months ever in relative terms in January. The reason for this was a dramatic style rotation from Growth to Value, one of the fastest that we have witnessed in over 30 years of managing Small & MidCap portfolios. The swift change in sentiment was due to a burst of global inflation, which stoked fears of interest rate rises and disproportionately hurt long duration assets, notably Growth Small & MidCap equities. To put things in context, the MSCI World Growth index underperformed its Value counterpart by a staggering 8.1% in January, the second largest such underperformance in almost 50 years (only topped by April 1999, when Value enjoyed a brief respite amidst the dot-com frenzy).

The outperformance of Value continued in February, albeit not with the same vigour as we had seen earlier in the year. While inflation remained a dominant theme, another far more serious moment of historical significance impacted markets on 24 February 2022. Russia launched the largest military attack in Europe since World War Two by invading Ukraine, further shaking the confidence of equity investors. None of our Funds has ever had (or will have) direct exposure to Russia or Eastern Europe.

**Portfolio**

The NAV of the share class declined by 19% in Euro terms during the first quarter, an underperformance of 9% versus the MSCI Europe Small Cap benchmark index. Much of this underperformance came in January and it was reassuring to see the NAV rise in absolute terms in March and outperform its benchmark by 2%.

**The strongest contribution** during the quarter came from **MTU Aero Engines**, the German aircraft component maker, which outperformed as air travel returned to something approaching normal following the end of many covid restrictions. **Photocure**, that sells a drug used to help diagnose and treat bladder cancer, performed well following a key regulatory approval for its partner Karl Storz. **Marshalls**, the UK's leading hard landscaping manufacturer, rebounded in March after

the company reported good full year numbers alongside a strong outlook ahead of consensus expectations.

**The weakest contribution** came from **Esker**, the French provider of cloud software solutions that help companies to manage working capital, which weakened during the quarter as it was caught up in the sell-off of high growth tech companies, while increased investments reduced margin expectations. **Vitrolife**, the provider of equipment and services to fertility clinics, underperformed as analysts assessed with caution the rationale of its major acquisition of genetic test services business Igenomix. **Thule**, the manufacturer of sports and outdoor goods, remained broadly flat despite persistent concerns about the robustness of its end markets, such as recreational vehicles plagued by the chassis shortage.

### **Outlook**

In times of market turbulence, it is easy to get distracted by the noise of headlines. There have been many such distractions over the quarter, from worries about inflation to sombre updates from Ukraine. Against such a backdrop, we have been focusing as always on our companies and understanding how they are impacted by the pressures impacting the global economy. On the whole, the message has been reassuring. As with Marshalls, many have posted positive trading updates and some have come in ahead of consensus expectations. The environment has allowed us to invest in and add to companies whose valuations have fallen due to negative sentiment, rather than a deterioration in the underlying fundamentals.

**Finally, it is worth noting that the entire Montanaro team invested additional capital in our Funds in Q1. We are aligned with our clients and share the ups and downs of markets with you.**

*As well as the investment implications of the Ukraine conflict, MAM is acutely aware of the human suffering that is occurring. In response to this, our team has collectively made a contribution to the 'Disaster Emergency Committee – Ukraine Humanitarian Appeal'. This contribution has been matched by MAM, providing a significant donation to help people affected by this escalating conflict. More information about this appeal can be found here: <https://www.dec.org.uk/appeal/ukraine-humanitarian-appeal>*

---

*The views expressed in this article are those of the author at the date of publication and not necessarily those of Montanaro Asset Management Ltd. The information contained in this document is intended for the use of professional and institutional investors only. It is for background purposes only, is not to be relied upon by any recipient, and is subject to material updating, revision and amendment and no representation or warranty, express or implied, is made, and no liability whatsoever is accepted in relation thereto. This memorandum does not constitute investment advice, offer, invitation, solicitation, or recommendation to issue, acquire, sell or arrange any transaction in any securities. References to the outlook for markets are intended simply to help investors with their thinking about markets and the multiple possible outcomes. Investors should always consult their advisers before investing. The information and opinions contained in this article are subject to change without notice.*